Pharming Group Company Profile (NASDAQ:PHGUF)

About Pharming Group (NASDAQ:PHGUF)

Pharming Group logoPharming Group NV (Pharming) is a Netherlands-based biotechnology company. The Company operates through two business segments, including Recombinant proteins, and DNage. Pharming focuses on the development, production and commercialization of human therapeutic proteins to be used as innovative therapies. The Company's products are aimed at treatments for genetic disorders and surgical and traumatic bleeding. Pharming's technologies include novel transgenic platforms for the production of biopharmaceuticals, as well as technology and processes for the purification and formulation of these biopharmaceuticals. The Company's commercial partners are: Santarus, Sobi, MegaPharm, Eczacibasi, Transmedic and Hyupjin. The Company operates worldwide. In March 2014, it announced downsizing of the Dutch operations following from strategic re-emphasis on collaborative development efforts and out-sourcing of non-core activities.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PHGUF
  • CUSIP: N/A
  • Web: www.pharming.com/
Average Prices:
  • 52 Week Range: $0.18 - $0.70
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 34.25
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: $49.34 million
  • Price / Sales: N/A
  • Book Value: $0.02 per share
  • Price / Book: 40.29
Profitability:
  • EBIDTA: $1.17 million
 

Frequently Asked Questions for Pharming Group (NASDAQ:PHGUF)

What is Pharming Group's stock symbol?

Pharming Group trades on the NASDAQ under the ticker symbol "PHGUF."

How were Pharming Group's earnings last quarter?

Pharming Group (NASDAQ:PHGUF) issued its quarterly earnings results on Thursday, March, 5th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.04 by $0.01. View Pharming Group's Earnings History.

When will Pharming Group make its next earnings announcement?

Pharming Group is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Pharming Group.

Who are some of Pharming Group's key competitors?

Who are Pharming Group's key executives?

Pharming Group's management team includes the folowing people:

  • Paul Jai Sekhri, Chairman of the Board of Supervisory Directors
  • Sijmen de Vries, Member of the Management Board, Chief Executive Officer
  • Juergen H. L. Ernst, Vice Chairman of the Board of Supervisory Directors
  • Robin Wright, Chief Financial Officer, Member of the Management Board
  • Bruno M. Giannetti, Member of the Management Board, Chief Operations Officer
  • Anne-Marie de Groot, Senior Vice President Organizational Development, Member of the Management Board
  • Jaap Blaak, Member of the Board of Supervisory Directors
  • Aad de Winter, Member of the Board of Supervisory Directors
  • Jan H. Egberts M.D., Member of the Board of Supervisory Directors
  • Jonh Barrie Ward Ph.D., Member of the Board of Supervisory Directors

How do I buy Pharming Group stock?

Shares of Pharming Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pharming Group's stock price today?

One share of Pharming Group stock can currently be purchased for approximately $0.69.


MarketBeat Community Rating for Pharming Group (NASDAQ PHGUF)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  40 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  103
MarketBeat's community ratings are surveys of what our community members think about Pharming Group and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Pharming Group (NASDAQ:PHGUF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pharming Group (NASDAQ:PHGUF)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Pharming Group (NASDAQ:PHGUF)
Earnings by Quarter for Pharming Group (NASDAQ:PHGUF)
Earnings History by Quarter for Pharming Group (NASDAQ PHGUF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/26/2017        
3/5/2015$0.04$0.05ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pharming Group (NASDAQ:PHGUF)
Current Year EPS Consensus Estimate: $-0.070 EPS
Next Year EPS Consensus Estimate: $0.020 EPS

Dividends

Dividend History for Pharming Group (NASDAQ:PHGUF)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Pharming Group (NASDAQ:PHGUF)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Pharming Group (NASDAQ:PHGUF)
Latest Headlines for Pharming Group (NASDAQ:PHGUF)
Source:
DateHeadline
americanbankingnews.com logoPharming Group (PHGUF) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - September 12 at 7:02 AM
americanbankingnews.com logoZacks: Brokerages Expect Pharming Group (PHGUF) Will Announce Quarterly Sales of $18.76 Million
www.americanbankingnews.com - September 11 at 3:26 PM
americanbankingnews.com logoZacks: Analysts Anticipate Pharming Group (PHGUF) Will Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - September 9 at 4:04 AM
americanbankingnews.com logoPharming Group (PHGUF) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - August 29 at 8:44 AM
americanbankingnews.com logo$18.76 Million in Sales Expected for Pharming Group (PHGUF) This Quarter
www.americanbankingnews.com - August 23 at 11:06 AM
americanbankingnews.com logoZacks Investment Research Lowers Pharming Group (PHGUF) to Sell
www.americanbankingnews.com - August 23 at 6:52 AM
americanbankingnews.com logoZacks: Brokerages Expect Pharming Group (PHGUF) to Post -$0.01 Earnings Per Share
www.americanbankingnews.com - August 21 at 12:20 PM
americanbankingnews.com logoPharming Group (NASDAQ:PHGUF) Expected to Post Quarterly Sales of $18.76 Million
www.americanbankingnews.com - August 5 at 7:42 AM
americanbankingnews.com logoZacks: Pharming Group (PHGUF) Receives Consensus Rating of "" from Brokerages
www.americanbankingnews.com - March 29 at 12:19 PM
americanbankingnews.com logoPharming Group Expected to Post Q3 2017 Earnings of $0.00 Per Share (PHGUF)
www.americanbankingnews.com - March 13 at 11:38 AM
seekingalpha.com logoPharming Bets The House On Ruconest
seekingalpha.com - November 24 at 10:11 AM
seekingalpha.com logoPharming Bets The House On Ruconest - Seeking Alpha
seekingalpha.com - November 23 at 10:01 AM
seekingalpha.com logoA European Biotech Stock Basket For 2016 - Seeking Alpha
seekingalpha.com - January 27 at 11:43 AM

Social

Chart

Pharming Group (PHGUF) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff